Literature DB >> 6816798

Characterization of the biosynthetic pathway of prostaglandin D2 in human platelet-rich plasma.

T Watanabe, S Narumiya, T Shimizu, O Hayaishi.   

Abstract

The biosynthetic mechanism of prostaglandin D2 in human platelet-rich plasma has been investigated. Platelet-rich plasma was separated into washed platelets and platelet-poor plasma, and [1-14C]prostaglandin H2 was incubated with each fraction. The enzymatic conversion of the endoperoxide to prostaglandin D2 was found only in platelet-poor plasma and not in washed platelets or platelet lysate. This prostaglandin D synthetase activity was purified to homogeneity and identified as serum albumin by sodium dodecyl sulfate polyacrylamide gel electrophoresis, isoelectric focusing, and immunoelectrophoresis. The optimal pH and Km value for prostaglandin H2 were 9.0 and 6 microM, respectively. Glutathione was not required for the activity. Although prostaglandin H2 ws converted to prostaglandin D2 and E2 in the reaction, only the prostaglandin D2 formation was dependent on the protein amount and abolished by prior boiling. The action of this activity under physiological conditions was examined in a model system constituted of serum albumin and washed platelets. Prostaglandin D2 formation was observed in association with thrombin-evoked platelet aggregation in this system and was proportional to the number of platelets and the concentration of serum albumin, suggesting that thrombin-stimulated platelets released prostaglandin H2, and the latter compound was then converted to prostaglandin D2 by the action of serum albumin. Consistent with this interpretation, prostaglandin H2 added to platelet-rich plasma was converted in part to prostaglandin D2, and the aggregation caused by this endoperoxide was greatly enhanced by neutralizing the action of prostaglandin D2 with anti-prostaglandin D2 antiserum.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6816798

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.

Authors:  Wen-Liang Song; Jane Stubbe; Emanuela Ricciotti; Naji Alamuddin; Salam Ibrahim; Irene Crichton; Maxwell Prempeh; John A Lawson; Robert L Wilensky; Lars Melholt Rasmussen; Ellen Puré; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 2.  Current concepts for a drug-induced inhibition of formation and action of thromboxane A2.

Authors:  H Patscheke
Journal:  Blut       Date:  1990-05

Review 3.  Unusual properties of the cytochrome P450 superfamily.

Authors:  David C Lamb; Michael R Waterman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

4.  Structural insights into human serum albumin-mediated prostaglandin catalysis.

Authors:  Jinsheng Yang; Charles E Petersen; Chung-Eun Ha; Nadhipuram V Bhagavan
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

5.  Protectin DX, a double lipoxygenase product of DHA, inhibits both ROS production in human neutrophils and cyclooxygenase activities.

Authors:  Miao Liu; Tarek Boussetta; Karama Makni-Maalej; Michèle Fay; Fathi Driss; Jamel El-Benna; Michel Lagarde; Michel Guichardant
Journal:  Lipids       Date:  2013-11-20       Impact factor: 1.880

Review 6.  Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease.

Authors:  Eitan A Friedman; Martin L Ogletree; Elias V Haddad; Olivier Boutaud
Journal:  Thromb Res       Date:  2015-05-28       Impact factor: 3.944

7.  Characterization and biological effects of di-hydroxylated compounds deriving from the lipoxygenation of ALA.

Authors:  Miao Liu; Ping Chen; Evelyne Véricel; Moreno Lelli; Laetitia Béguin; Michel Lagarde; Michel Guichardant
Journal:  J Lipid Res       Date:  2013-06-05       Impact factor: 5.922

8.  Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients.

Authors:  Y Eguchi; N Eguchi; H Oda; K Seiki; Y Kijima; Y Matsu-ura; Y Urade; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

9.  9-Deoxy-delta 9, delta 12-13,14-dihydroprostaglandin D2, a metabolite of prostaglandin D2 formed in human plasma.

Authors:  Y Kikawa; S Narumiya; M Fukushima; H Wakatsuka; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

10.  Blood plasma influences anti-aggregatory potency of prostaglandins: effect of albumin.

Authors:  G Kobzar; V Mardla; I Järving; N Samel
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.